Twitter sheds light on college students’ med misuse
MOUNT PROSPECT, Ill. — College students are using popular social media platform Twitter to talk about prescription drugs, and it turns out those brief, 140-character messages are saying a lot about medication abuse and misuse, according to the National Association of Boards of Pharmacy.
Researchers from the University of Pennsylvania monitored over 2,000 tweets over a one-week period and discovered that 60% to 70% of the tweets mentioned drug abuse and medication misuse.
Another study from Brigham Young University analyzed over 213,000 tweets over the period of Nov. 2011 to May 2012, all of which mentioned the word “Adderall.” The study revealed that mentions of the drug increased during college exam periods, shedding even more light on the fact that a great deal of students use the drug with the intention of increasing their concentration and productivity during exam time.
Fruth Pharmacy promotes Tim Weber to VP
POINT PLEASANT, W.Va. — Fruth Pharmacy has promoted director of pharmacy administration and procurement Tim Weber to VP, the regional retail pharmacy chain said Thursday.
In the new position, Weber will lead the chain’s pharmacy division. He previously held positions at Eckerd Drug Company and Sears Holdings.
"One of our best successes to date is our migration from legacy PDX to a workflow-orientated Enterprise Pharmacy System," Weber said. "This system enables Fruth to optimize the filling process and gives our pharmacy teams more functionality within the daily workflow to better serve our patients. Fruth has been able to advance our clinical services to our patients due to this improvement by integrating medication therapy management into the pharmacy workflow."
Mylan launches cabergoline tablets
PITTSBURGH — Mylan has launched a generic drug for treating a condition that causes heightened levels of the protein prolactin in the blood, the company said Thursday.
Mylan announced the launch of cabergoline tablets in the 0.5-mg strength, used for treating hyperprolactinemic disorders.
Various versions of the drug had sales of about $41.67 million during the 12-month period ending in September, according to IMS Health.